Cannabis sativa subsp. sativa's pharmacological properties and health effects: A scoping review of current evidence
- PMID: 33465140
- PMCID: PMC7815160
- DOI: 10.1371/journal.pone.0245471
Cannabis sativa subsp. sativa's pharmacological properties and health effects: A scoping review of current evidence
Abstract
Introduction: Hemp (Cannabis sativa subsp. sativa), commonly used for industrial purposes, is now being consumed by the public for various health promoting effects. As popularity of hemp research and claims of beneficial effects rises, a systematic collection of current scientific evidence on hemp's health effects and pharmacological properties is needed to guide future research, clinical, and policy decision making.
Objective: To provide an overview and identify the present landscape of hemp research topics, trends, and gaps.
Methods: A systematic search and analysis strategy according to the preferred reporting items for systematic review and meta-analysis-ScR (PRISMA-ScR) checklist on electronic databases including MEDLINE, OVID (OVFT, APC Journal Club, EBM Reviews), Cochrane Library Central and Clinicaltrials.gov was conducted to include and analyse hemp research articles from 2009 to 2019.
Results: 65 primary articles (18 clinical, 47 pre-clinical) were reviewed. Several randomised controlled trials showed hempseed pills (in Traditional Chinese Medicine formulation MaZiRenWan) improving spontaneous bowel movement in functional constipation. There was also evidence suggesting benefits in cannabis dependence, epilepsy, and anxiety disorders. Pre-clinically, hemp derivatives showed potential anti-oxidative, anti-hypertensive, anti-inflammatory, anti-diabetic, anti-neuroinflammatory, anti-arthritic, anti-acne, and anti-microbial activities. Renal protective effects and estrogenic properties were also exhibited in vitro.
Conclusion: Current evidence on hemp-specific interventions are still preliminary, with limited high quality clinical evidence for any specific therapeutic indication. This is mainly due to the wide variation in test item formulation, as the multiple variants of this plant differ in their phytochemical and bioactive compounds. Future empirical research should focus on standardising the hemp plant for pharmaceutical use, and uniformity in experimental designs to strengthen the premise of using hemp in medicine.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Danielewicz D, Surma-Ślusarska B. Properties and fibre characterisation of bleached hemp, birch and pine pulps: a comparison. Cellulose. 2017;24(11):5173–86. 10.1007/s10570-017-1476-6 - DOI
-
- Cherney JH, Small E. Industrial hemp in North America: production, politics and potential. Agronomy. 2016;6(4):58 10.3390/agronomy6040058 - DOI
-
- van der Werf HMG, Harsveld van der Veen JE, Bouma ATM, ten Cate M. Quality of hemp (Cannabis sativa L.) stems as a raw material for paper. Ind Crops Prod. 1994;2(3):219–27. 10.1016/0926-6690(94)90039-6. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
